2009-11-27 08:31:35 - New Pharmaceuticals research report from Datamonitor: "Commercial Insight: Hormonal Contraceptives - Look beyond oral contraception for a competitive edge"

Since the 1960s, hormonal contraceptives have been widely used as effective birth control in the developed world. Although they are mainly used to prevent pregnancies, they can be used for treating other conditions such as acne, endometriosis, and polycystic ovarian syndrome. In 2008, the hormonal contraceptives market was worth $6.2 billion across the seven major pharmaceutical countries.

Scope

* Analysis of

the global hormonal contraceptive prescriptions from 200408, split by geographical region, drug class, indication, and brand.
* Discussion of key commercial opportunities and threats in the US, Japan, and five major European markets.
* In depth profiles of key current hormonal contraceptive brands and pipeline agents with SWOT analyses and country-specific sales forecasts to 2018.
* Detailed analysis of key developer trends, strategies and portfolios including a case study of Bayer-Schering's Yasmin franchise.


Highlights

Sales of hormonal contraceptives in the seven major markets accounted for 68% of the global market value. Over the forecast period 2009-2018, the market is expected to grow due to the launch of novel natural estrogen products, which will be well received in the US in particular, and the launch of new prescription emergency contraceptives in the EU.

The market offers opportunities for current and future market players. In addition to indication expansions, there is the need to develop delivery mechanisms that will increase compliance and efficacy. However, the current market environment poses several threats to market growth such as the high litigation pressure and the need to cut sales forces

Marketing is a key tool for companies in this market to increase sales of their brands. Datamonitor recommends that companies should also focus on marketing the secondary benefits of taking hormonal contraceptives, such as the decreased risk of gynecological cancers, to increase acceptance of contraceptives.

Reasons to Purchase

* Understand historical (200408) and future (20092018) hormonal contraceptive drug market dynamics and competitive environment.
* Gain insight into the main opportunities and threats specific to the hormonal contraceptive market.
* Evaluate the sales forecasts of marketed, generic, and key pipeline drugs to 2018 in the US, Japan, France, Germany, Italy, Spain, and the UK.


Partial Table of Contents:
-- Full ToC is available at www.fastmr.com/catalog/product.aspx?productid=43006&dt=t

ABOUT DATAMONITOR HEALTHCARE
About the Genitourinary pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor insight into the disease market
Related reports
Upcoming related reports
CHAPTER 2 MARKET DEFINITION
Introduction
Market definition for this report
CHAPTER 3 MARKET OVERVIEW
Seven major markets
Current and future market overview
Regional market dynamics - The US was the largest hormonal contraceptive market in 2008
Drug class dynamics - monophase preparations <50mcg estrogen will remain clear market leader
Indication analysis - hormonal contraceptives are mostly used for contraception
Drug analysis - Mirena will become market leader by 2018 despite generic erosion in the US
Opportunities and threats
Opportunity 1 - there is the need to develop new administration propositions that will increase real world drug efficacy
Opportunity 2 - switch to over-the-counter sales
Opportunity 3 - emergency contraceptives is a growth market
Opportunity 4 - education and public relations increase awareness of hormonal contraceptives
Opportunity 5 - development of male hormonal contraceptives
Threat 1 - safety concerns over hormonal treatments can hamper hormonal contraceptive sales
Threat 2 - sales force and marketing budget cuts
US
Current and future market assessment
The US market will continue to grow up to 2018
G3A1 (Monophase preparation <50mcg estrogen) will continue to dominate the market
Use of natural estrogen likely to be perceived as safer by women in the US and will drive market growth
Opportunities and threats
Opportunity 1 - new government administration will support better access to hormonal contraceptives
Opportunity 2 - increase in contraceptive coverage from insurers
Threat 1 - poor patent protection for oral contraceptives poses a threat to marketed brands
Threat 2 - the US market is dominated by high incursion of generic hormonal contraceptives
Threat 3 - continuous litigation in the hormonal contraceptive market will limit innovation and cause players to exit the market
Threat 4 - the US healthcare reform poses a threat to Pharma
Threat 5 - direct-to-consumer advertising may be restricted
Japan
Current and future market assessment
Hormonal contraceptive market in Japan remains highly underdeveloped
Japanese market is set to grow
Triphasic hormonal contraceptives are by far the most popular choice of hormonal contraceptive in Japan
Bayer-Schering is one of the leading companies in Japan too
Triquilar (levonorgestrel + ethinylestradiol, Bayer- Schering) will remain the market leading brand in 2018
Opportunities and threats
Opportunities


For more information or to purchase this report, go to www.fastmr.com/catalog/product.aspx?productid=43006

About Datamonitor

The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at www.fastmr.com/catalog/publishers.aspx?pubid=1002

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.